Kailera Therapeutics: Speculative Stock on Earth with Promising Weight-Loss Pipeline

Kailera Therapeutics (KLRA) is considered the most speculative stock by Jim Cramer due to its advanced metabolic pipeline and strong financial backing. The company's lead weight-loss candidate is in global Phase 3 trials, with a Phase 3 study in China showing a mean weight loss of up to 19.2%. Kailera had $1.17 billion in cash and marketable securities as of June 30, 2026, expected to fund operations into mid-2028. However, the company faces high cash burn and intense competition in the obesity treatment market. Twenty-two hedge funds had a stake in KLRA in Q2, with short interest of float sitting at 33.96%.